Objective-To investigate whether methotrexate (MTX) has a steroid sparing effect in the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
(GCA).
Methods-We carried out a randomised double blind, placebo controlled study in 40 patients with PMR, six of whom also had clinical symptoms of GCA. A temporal artery biopsy specimen was available from 37 patients; GCA was found in six of the specimens. Among the six patients with clinical signs of GCA, three had a positive biopsy specimen. All patients were started on prednisone 20 mg/day, irrespective of clinical signs and biopsy result, supplemented with a weekly, blinded capsule containing either MTX 7 5 mg or placebo. The prednisone dose was decreased as soon as clinical symptoms disappeared and erythrocyte sedimentation rate, C reactive protein level, or both, had normalised. Results-Twenty one patients were followed for two years, or at least one year after discontinuing medication. No differences were found between the MTX group and the placebo group concerning time to achieve remission, duration of remission, number of relapses, or cumulative prednisone doses. After 21 weeks the mean daily prednisone dose was reduced by 50%. Forty percent of all patients were able to discontinue prednisone within two years. Median duration of steroid treatment was 47 5 weeks (range . No serious complications from GCA were encountered. Conclusions-With a (rapid) steroid tapering regimen, it was possible to reduce the mean daily prednisone dose by 50% in 21 weeks and to cease prednisone in 40%/o of the patients within two years. With this regimen, no steroid sparing effect of MTX in a dosage of 7 5 mg/week was found.
(Ann Rheum Dis 1996; 55: 218-223) Polymyalgia rheumatica (PMR) is a clinical syndrome of older patients, characterised by pain and stiffness in the neck, shoulders, or hips that persists for at least a month. The onset of disease usually is abrupt, but may be preceded for months by malaise, depression and loss of weight. The erythrocyte sedimentation rate (ESR) is almost always strongly increased and symptoms usually respond very well to a small dose of prednisone (10-20 mg/day). PMR can occur in combination with giant cell arteritis (GCA). Manifestations of GCA are headache, tenderness of the scalp, especially over the temporal arteries, jaw claudication, and visual loss. PMR and GCA frequently coexist, but the percentages of concurrence vary in different populations.' 2 Some authors consider PMR and GCA as different manifestations of the same underlying process. 3 Corticosteroid treatment usually induces prompt relief of symptoms, and some authors consider this dramatic response to be one of the diagnostic criteria for both diseases. 2 4 The ideal initial prednisone dose, tapering scheme, and duration of treatment are much debated."'0 Current opinion is that alteration in steroid dose should be based predominantly on clinical signs and symptoms as an increase in ESR or C reactive protein (CRP) does not always predict relapse; that treatment usually lasts at least two years; and that relapses are most frequent within the first one or two months (related to attempted reduction of steroid dose) and within one year ofwithdrawal of steroids. 4 1112 Usually, GCA is treated with high doses of prednisone (1 mg/kg/day) for fear of ocular complications. However, corticosteroid treatment does not always prevent blindness and, furthermore, a clear relation has been found between initial and cumulative prednisone doses and side effects. ' rence of the original symptoms and an increase of 100% in ESR or CRP after stopping prednisone and trial medication. An increase in ESR without symptoms was not considered sufficient evidence of relapse or recurrence. In the event of relapse, the current prednisone dose was doubled (to a maximum of 20 mg/day) until symptoms disappeared and ESR or CRP normalised. The tapering scheme described above was then resumed.
Follow up was every three to six weeks until the patient achieved remission, after which the patient's visits were scheduled every three months up to two years or at least one year after withdrawal from medication. On each visit, the patient was asked about muscle pain or stiffness, morning stiffness, malaise, headache, visual disturbances, and jaw claudication. Body weight and blood pressure were recorded. ESR, CRP, full blood count, creatinine, AST, ALT, glucose and albumen were measured. The number of adverse effects was noted: gastrointestinal complaints, oral ulceration, hair loss, rash, osteoporosis, and infections.
STATISTICS
Differences in continuous variables between groups were analysed with the two tailed Student's t test. Statistical significance of differences in binomial or categorised variables was assessed with x2 tests with the Yates' correction; in the event of small numbers, Fisher's exact test was used. Significance was accepted for p < 0-05. Medians and range are given for variables that did not show a normal distribution. All analyses were performed with the statistical package SPSS-PC + 4 0.
Results

PATIENTS
Forty patients (30 women, 10 men) were included in the study: 20 in the MTX group and 20 in the placebo group. Mean age was 70 9 years (range 53-84). All patients presented with symptoms of PMR and six also had signs of GCA. Twenty one patients were followed up to two years, or at least one year after discontinuing medication. Fourteen patients withdrew from the study during the first year: four in the MTX group and 10 in the placebo group (table 1). In the second year, another five patients from the MTX group withdrew, but none from the control group did so. Data of all patients were included in the study results until the time of their withdrawal, reasons for which are shown in table 1. One patient died during the study period, two weeks after reaching remission. Five patients died after withdrawal. Causes of death were malignancy (three cases), multiorgan failure (possibly as a result of amyloidosis: one case) and cardiac death (two cases). There was no evidence that arteritis or trial medication was related to cause of death. In three patients, the steroid scheme was violated so that evaluation was no longer possible: one patient needed intravenous administration of steroids because which the medication was interrupted and, in error, not restarted after normalisation; one patient was depressed and refused to continue taking the capsules. In both groups, many side effects were encountered that did not lead to withdrawal (table 2). All patients experienced at least one adverse effect; the number of effects experienced varied from one (six patients) to eight (two patients). Twenty five patients (63%) experienced an increase in body weight (2 1 kg) and 19 patients (48%) had an increase in blood pressure (2 5 mm Hg diastolic or systolic); overt hypertension (diastolic pressure 2 100 mm Hg or systolic pressure .200 mm Hg) occurred in 14 patients (35%).
The total number of patient-weeks of follow up was 2906 (1624 for the MTX group and 1282 for the placebo group) and the mean duration of follow up in the two groups was 81 2 and 64 1 weeks, respectively. Because of these differences between the two groups, data on cumulative prednisone dosages, duration of prednisone treatment, and number of relapses were corrected for the number ofpatient-weeks per group.
TEMPORAL ARTERY BIOPSY
Thirty seven patients gave their permission for the removal of a temporal artery biopsy specimen before starting treatment. Six patients had at least two clinical signs of GCA (table 3); in only three of them was histological proof of arteritis found in the biopsy specimen. In three other patients without clinical evidence of GCA, biopsy revealed arteritis. Positive biopsy results were distributed equally between the groups (n = 3 in each group). No correlation was found between clinical signs and biopsy results (table 3). The one patient who had four signs of GCA (headache, visual symptoms, jaw claudication, and tender temporal arteries on palpation) and a positive biopsy result had to be withdrawn from the study after 10 (range 30-100); that in the placebo group was 45 weeks (range 22-104). Median duration of remission was 7 weeks (range 1-74) and 35 weeks (range 0-71), respectively. These differences were not statistically significant. Duration of remission varied widely and did not seem to be correlated with the time to achieve remission ( Eleven patients achieved remission in 30-70 weeks (median 45) and maintained remission throughout the study. Nine patients had a recurrence of symptoms after discontinuing medication; five of them were still taking steroids after two years of follow up. One patient was never able to withdraw completely from prednisone. Many relapses were seen, most frequently with prednisone doses <7-5 mg/day, requiring dose adjustment. Although, at the start of the study, we defined relapse as a combination of clinical symptoms and increase in ESR or CRP, it was not always possible to put these criteria strictly into practice. Sometimes patients increased their dose between visits to the outpatient clinic, without ESR or CRP being measured. Therefore, from a pragmatic point of view, all increases in prednisone dose were considered as relapse.
No differences were found between the MTX group and the placebo group concerning the time to achieve remission, duration of remission, or number of relapses. Duration of remission was shorter in the MTX group, in which seven of 11 patients had a recurrence, than in the placebo group, in which two of nine patients had a recurrence. However, this clinically relevant difference did not reach statistical significance. An explanation for a more rapid recurrence in the MTX group could be the rather quick discontinuation of MTX, six weeks after stopping prednisone. It is possible that, as in rheumatoid arthritis, a flare of disease activity occurs after stopping MTX. No differences were found between the two groups in the prednisone tapering regimen, median prednisone dose needed to achieve remission, cumulative doses after one and two years, or duration of steroid treatment. Furthermore, by combining the most relevant outcome variables (time to achieve remission, duration of remission, number of relapses, cumulative prednisone doses) into a pooled index,18 we were still not able to demonstrate a difference between the groups. The conclusion from our data is that MTX in a dosage of 7*5 mg/week does not have a steroid sparing effect in the treatment of PMRIGCA. However, the high recurrence rate in the MTX group, possibly as a result of a flare of disease activity induced by discontinuation of MTX, might suggest at least some effect of MTX. It could be possible that the MTX dose that we used was not large enough; Hernandez et al'6 used a dose of 10 mg/week in their pilot study on GCA, Krall et al found a steroid sparing effect ofMTX for corticosteroid resistant PMR and GCA at a dose of 12 No correlation was found between the time to achieve remission and the time of recurrence (table 4) . No variables were found to be indicative for rapid response to treatment, relapse rate, or chance of recurrence. In contrast with other studies, we found that many patients were able to stop corticosteroid treatment within two years: 15 (71 5%) of the 21 patients who completed the study and at least 16 (40%) of the initial group of 40 patients. In common with other authors, we seemed to find two populations of patients: one group with a self limiting disease, and another with a more persistent process.8
Despite the relatively low cumulative dose of steroid, many adverse effects were seen, most of which were probably attributable to prednisone. Adverse effects were reported in 65% of the follow up visits of the MTX group and in 70% for the placebo group. All patients experienced at least one side effect: increase in body weight (63%, 2 1 kg) and blood pressure (48%) were noted most frequently. Our data are consistent with those from an earlier prospective study which found an incidence of 36% of steroid associated side effects or, if weight gain was included, 76%.'3 It should be pointed out, however, that weight loss before entry to the study, as a result of the disease, was not accounted for.
No differences in the clinical course were found between patients presenting with symptoms of PMR only or PMR and GCA, with or without a positive temporal artery biopsy result. We did not find a correlation between biopsy result and clinical presentation ( 
